CEPI and SK bioscience partner to advance mRNA vaccine technology

CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus

Quizartinib granted priority review in the U.S.

Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone

Novartis maintains growth momentum; Confirms FY’22 Group guidance

Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.

Zydus receives final approval from USFDA for Micafungin for Injection

Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data

Biocon Biologics insulins facility in Malaysia receives EU GMP Certification

The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.

Lupin launches Paliperidone Extended-Release Tablets in US

Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).

Aster DM Healthcare to acquire Sr Sainatha Multispeciality Hospitals

Jubilant Pharmova Q2FY23 consolidated PAT drops to Rs. 5.49 Cr

The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.

Glenmark Life Sciences Q2FY23 PAT slips to Rs. 106.87 Cr

The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.

Glenmark launches Zita D for adults with Type 2 diabetes having comorbidities

A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities